Document is current
Any future updates will be listed below
-
Authors
Roslund, Marja I.
Uimonen, Laura
Kummola, Laura
Cerrone, Damiano
Ojala, Ann
Luukkonen, Anna
Holopainen, Ella
Korhonen, Aku
Penttilä, Reijo
Saarenpää, Mika
Venäläinen, Martti
Haveri, Hanna
Rajaniemi, Juho
Laitinen, Olli H.
Sinkkonen, Aki
group, the BIWE research
-
Funding
Funding for this research was provided by:
Strategic Research Council (346136)
Strategic Research Council (346137)
Strategic Research Council (346138)
- License Information
-
More Information
Article History
Received: 17 January 2025
Accepted: 23 March 2026
First Online: 15 May 2026
Declarations
Ethics approval and consent to participate: The study strictly followed the recommendations of the “Finnish Advisory Board on Research Integrity”, and it received ethical approval from the HUS Committee on Medical Research Ethics (Helsinki University Hospital District). All participants received oral and written information about the study and provided written, informed consent in accordance with the Declaration of Helsinki. The trial has been registered in ClinicalTrials.gov (ID NCT06353035), first posted date 2024-04-03.
Consent for publication: Not applicable.
Competing interests: A.S. and O.H.L. are co-inventors in a patent ‘Probiotic immunomodulatory compositions’ (U.S. patent no. 11318173, U.S. Patent and Trademark Office). A.S. and O.H.L. are shareholders and members of the board of Uute scientific Ltd which develops immunomodulatory treatments.
